



Pulmonary aspergillosis complicating non-influenza respiratory viral infections (non-flu-RVI)



among solid organ transplant (SOT) recipients


Anna Apostolopoulou, Cornelius J Clancy, J. Alex Viehman, M. Hong Nguyen

Division of Internal Medicine and Division of Infectious Diseases, University of Pittsburgh Medical Center

BACKGROUND

- Invasive pulmonary aspergillosis (IPA) complicating influenza (flu) has been increasingly recognized
- Our group has shown that 22% of SOT patients developed IPA after flu infection
- Respiratory viral infections (flu and non-flu RVI) can cause direct damage to the respiratory epithelium and decreased ciliary clearance → development of secondary infections, including IPA
- The goal of this study was to evaluate the rate of IPA after RVI due to adenovirus (ADV), parainfluenza (PIV) or respiratory syncytial virus (RSV) among SOT recipients

Fig. 1. Rates of non-flu RVI per types of transplanted organ and viruses



C. Risk Factors for RVI-associated IPA

	IPA (N=10)	No IPA (N=246)	p-value
Median cumulative steroid dose at 7 days after RVI (mg of prednisone-equivalent dose)	96	35	0.02
Receipt of total prednisone dose of ≥140 mg at 7 days after RVI	50% (5)	5.3% (13)	<0.0001 *

* Odds ratio= 17.9 (95% CI: 4.6-69.8)

METHODS

- Retrospective chart review of SOT performed from Jan 2010-Dec 2017
- IPA was defined according to revised EORTC/MSG criteria and had to occur within 100 days of non-flu-RVI
- Colonization (COL) was defined as recovery of mold from airways in absence of IPA
- Statistical analyses: Fisher's exact test (binary variables); Wilcoxon's (continuous variables)

B. Epidemiology of IPA post-non-flu-RVI

- 17% (44/256) of SOT recipients had *Aspergillus* recovered from respiratory culture within 100 days of non-flu-RVI (Fig. 2)
 - IPA (N=10): 7 proven, 3 probable; 36 colonization (COL)
- Median time from non-flu-RVI to *Aspergillus* (+) culture = 29 days
- 36% of pts were treated with a mold-active azole after an *Aspergillus* (+) culture

Fig. 2. Recovery of *Aspergillus* post-RVI per virus





Fig. 3. ROC curve for cut-off of cumulative prednisone-equivalent dose that discriminates IPA from non-IPA



RESULTS

A. Epidemiology of non-flu RVI (Fig. 1)

- 3,077 SOT were included. Incidence of non-flu RVI in SOT was 8.3% (256/3,077)
- Most prevalent was PIV (N=113, 44%), followed by RSV (N=104, 41%) and ADV (N=39, 15%)
- Median time from day of transplant to non-flu RVI = 18.1 months
- 59% of SOT pts with non-flu-RVI required admission, and 64% received augmented steroids. ADV was associated with longer hospital stay (median 14.5 days) than PIV (6.5 days) or RSV (6 days) (p=0.004).

CONCLUSIONS

- IPA and COL occurred in 4% and 13% of non-flu RVI in SOT patients, respectively.
 - Routine antifungal prophylaxis is not recommended in SOT with non-flu RVI
- Augmented steroids can likely increase incidence of IPA in SOT recipients.
 - The value of prophylaxis for SOT patient with recent steroid augmentation should be studied